Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALO ALTO, CALIF., AUG. 13, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX) , AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT THE REGISTRATION STATEMENT ON FORM S-4 (THE REGISTRATION STATEMENT), RELATED TO THE PREVIOUSLY ANNOUNCED PROPOSED BUSINESS COMBINATION (THE BUSINESS COMBINATION) BETWEEN DENALI CAPITAL ACQUISITION CORP. ("DENALI") (OTCB: DNQAF), A SPECIAL PURPOSE ACQUISITION COMPANY, AND SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX, HAS BEEN DECLARED EFFECTIVE BY THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC").

SCILEX HOLDING COMPANY (NASDAQ: SCLX) ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT ON FORMS-4 FOR THE PROPOSED BUSINESS COMBINATION OF DENALI CAPITAL ACQUISITION CORP. AND SEMNUR PHARMACEUTICALS, INC., A MAJORITY-OWNED SUBSIDIARY OF SCILEX

PALO ALTO, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE BOARD) HAS APPROVED A DEFERRAL OF THE PREVIOUSLY ANNOUNCED RECORD DATE OF MAY 2, 2025 FOR THE COMPANY'S PREVIOUSLY ANNOUNCED DIVIDEND OF SCILEX PREFERRED STOCK (THE DIVIDEND) TO ITS STOCKHOLDERS AND CERTAIN OTHER SECURITYHOLDERS OF SCILEX. THE NEW RECORD DATE FOR THE DIVIDEND WILL BE SUCH LATER DATE TO BE DETERMINED IN THE SOLE DISCRETION OF THE BOARD (SUCH LATER RECORD DATE AS SO DETERMINED BY THE BOARD, THE NEW RECORD DATE). THE BOARD RETAINS THE RIGHT TO CONTINUE TO CHANGE ANY NEW RECORD DATE (AND THEREFORE ANY RELATED PAYMENT DATE FOR THE DIVIDEND) AND THE ABILITY TO REVOKE THE DIVIDEND.

SCILEX HOLDING COMPANY ANNOUNCES DEFERRAL OF RECORD DATE FOR ITS PREVIOUSLY ANNOUNCED DIVIDEND OF PREFERRED STOCK EXCHANGEABLE FOR UP TO 10% OF SCILEX'S OWNERSHIP INTEREST IN SEMNUR PHARMACEUTICALS, INC., ITS WHOLLY OWNED SUBSIDIARY FROM MAY 2, 2025 TO A FUTURE DATE TO BE DETERMINED BY THE BOARD

PALO ALTO, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED A PUBLICATION ON GLOPERBA DOSING ADJUSTMENTS IN PEER-REVIEW JOURNAL.

SCILEX HOLDING COMPANY ANNOUNCES PUBLICATION ON GLOPERBA DOSING ADJUSTMENTS IN PEER-REVIEW JOURNAL

PALO ALTO, CALIF., MAY 16, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY PRESENTED THE PRESENTATION OF POST-HOC ANALYSIS OF THE C.L.E.A.R. TRIAL (CORTICOSTEROID LUMBAR EPIDURAL ANALGESIA IN RADICULOPATHY) INTERPRETING CLINICAL MEANINGFULNESS OF SAFETY AND EFFICACY OF SP-102 (SEMDEXA) FOR THE TREATMENT OF LUMBOSACRAL RADICULAR PAIN (LRP) AT THE 27TH ANNUAL MEETING OF AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS (ASIPP), MAY 15-17, 2025 IN ORLANDO, FL.

SCILEX HOLDING COMPANY PRESENTED POST-HOC ANALYSIS OF THE C.L.E.A.R. TRIAL ON CLINICAL MEANINGFULNESS OF SAFETY AND EFFICACY OF SP-102 FOR THE TREATMENT OF LUMBOSACRAL RADICULAR PAIN (LRP) AT THE 27TH ANNUAL MEETING OF AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS (ASIPP), MAY 15-17, 2025 IN ORLANDO, FL

PALO ALTO, CALIF., MAY 01, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED AN UPCOMING PRESENTATION OF POST-HOC ANALYSIS OF THE C.L.E.A.R.

SCILEX HOLDING COMPANY TO PRESENT POST-HOC ANALYSIS OF THE C.L.E.A.R. TRIAL ON CLINICAL MEANINGFULNESS OF SAFETY AND EFFICACY OF SP-102 FOR THE TREATMENT OF LUMBOSACRAL RADICULAR PAIN (LRP) AT THE 27TH ANNUAL MEETING OF AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS (ASIPP), MAY 15-17, 2025 IN ORLANDO, FL.

PALO ALTO, CALIF., APRIL 30, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS RECEIVED NOTIFICATION FROM THE NASDAQ STOCK MARKET LLC THAT THE COMPANY HAS REGAINED COMPLIANCE WITH THE MINIMUM CLOSING BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5550(A)(2). TO REGAIN COMPLIANCE, THE COMPANY WAS REQUIRED TO MAINTAIN A MINIMUM CLOSING BID PRICE OF $1.00 PER SHARE FOR AT LEAST TEN CONSECUTIVE TRADING DAYS. THIS REQUIREMENT WAS MET ON APRIL 30, 2025.

SCILEX HOLDING COMPANY REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE RULE

PALO ALTO, CALIF., APRIL 22, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED CHANGING THE PREVIOUSLY ANNOUNCED RECORD DATE OF APRIL 11, 2025 FOR ITS PREVIOUSLY ANNOUNCED DIVIDEND OF SCILEX PREFERRED STOCK (THE DIVIDEND) TO ITS STOCKHOLDERS AND CERTAIN OTHER SECURITYHOLDERS OF SCILEX.

SCILEX HOLDING COMPANY ANNOUNCES CHANGE IN RECORD DATE FOR ITS PREVIOUSLY ANNOUNCED DIVIDEND OF PREFERRED STOCK EXCHANGEABLE FOR UP TO 10% OF SCILEX'S OWNERSHIP INTEREST IN SEMNUR PHARMACEUTICALS, INC., ITS WHOLLY OWNED SUBSIDIARY FROM APRIL 11, 2025 TO MAY 2, 2025

PALO ALTO, CALIF., APRIL 16, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN, FOLLOWING THE FORMATION OF ITS PROPOSED JOINT VENTURE WITH IPMC COMPANY, NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT FDA HAS APPROVED OUR REQUEST FOR THE ORPHAN DRUG DESIGNATION FOR COLCHICINE FOR THE TREATMENT OF PERICARDITIS.

SCILEX HOLDING COMPANY ANNOUNCES FDA HAS APPROVED OUR REQUEST FOR THE ORPHAN DRUG DESIGNATION FOR COLCHICINE FOR THE TREATMENT OF PERICARDITIS

ELYXYB IS A FIRST-LINE TREATMENT AND THE ONLY FDA-APPROVED, READY-TO-USE ORAL SOLUTION FOR THE ACUTE TREATMENT OF MIGRAINE, WITH OR WITHOUT AURA, IN ADULTS.1 ACCORDING TO MARKET DATA FROM 2018, IT WAS FOUND THAT MIGRAINE WAS MORE SEVERE THAN OTHER TYPES OF HEADACHES AND IT IMPACTED MORE THAN 2.7 MILLION CANADIANS, WITH THE CANADIAN MIGRAINE THERAPEUTICS MARKET ESTIMATED TO REACH APPROXIMATELY $400 MILLION BY 2025.2 THERE IS STRONG EVIDENCE FOR THE USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AS A FIRST-LINE TREATMENT FOR MIGRAINE. ELYXYB (CELECOXIB ORAL SOLUTION) IS IN THE SAME CLASS OF AGENTS, IS FAST ACTING, AND HAS THE POTENTIAL TO HAVE THE LOWEST GASTROINTESTINAL (GI) SIDE EFFECTS OF ALL NSAIDS.3 PALO ALTO, CALIF.

SCILEX HOLDING COMPANY ANNOUNCES APPROVAL OF A NEW DRUG SUBMISSION (NDS) FROM THE HEALTH CANADA'S PHARMACEUTICAL DRUGS DIRECTORATE, BUREAU OF CARDIOLOGY, ALLERGY AND NEUROLOGICAL SCIENCES FOR ELYXYB'S ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CANADA

PALO ALTO, CALIF., APRIL 11, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND, FOLLOWING THE FORMATION OF ITS PROPOSED JOINT VENTURE WITH IPMC COMPANY, NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT WILL EFFECT A REVERSE STOCK SPLIT OF ITS OUTSTANDING SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-35, TO BE EFFECTIVE AS OF 12:01 A.M. EASTERN TIME ON APRIL 15, 2025.

SCILEX HOLDING COMPANY ANNOUNCES 1-FOR-35 REVERSE STOCK SPLIT

PALO ALTO, CALIF., MARCH 26, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX OR COMPANY), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND, FOLLOWING THE FORMATION OF ITS PROPOSED JOINT VENTURE WITH IPMC COMPANY, IN NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, REITERATES THAT IT HAS APPEALED A LOWER COURT DECISION TO THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT IN WASHINGTON, DC AND WILL CONTINUE TO VIGOROUSLY PURSUE ITS INFRINGEMENT ACTION ON APPEAL AGAINST AVEVA DRUG DELIVERY SYSTEMS, INC. (AVEVA).

SCILEX HOLDING COMPANY HAS APPEALED LOWER COURT DECISION TO THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT IN WASHINGTON, DC AND WILL CONTINUE TO VIGOROUSLY PURSUE ITS INFRINGEMENT ACTION AGAINST AVEVA

Scilex Holding Company

SCLX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Scilex Holding Company

SCLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SCLX